指数富集的配体系统进化技术的发展及其在临床治疗中的应用

基于作为配基的寡核苷酸的三维立体结构，指数富集的配体系统进化（SELEX）技术能够筛选获得高效、特异结合靶分子的寡核苷酸适体。该配基由于其亲和力高、特异性强、免疫原性低、筛选周期短及适用范围广等特性，在临床诊断和疾病治疗中拥有多项优势，具有被研制成新型适体药物应用于临床的巨大潜力。本文从SELEX技术的发展、配基的修饰改造、临床治疗的优势、配基作为靶蛋白功能阻断剂和药物分子靶向载体进行的临床应用等几个方面，对寡核苷酸适体在临床疾病治疗中的应用进行综述。

The development of the SELEX technology and its application in clini cal treatment

Based on the three-dimensional structure of oligonucleotide ligands, systematic evol （SE of ligands by exponential LEX） techno specific oligonucl log eot molecular targets y can screen for e ide aptamer to co Due to its hig enrichment fficient and mbine with h affinity, strong specificity, low immunogenicity, short filtering cycle and wide range of application, the ligands have several advantages and potential for new drugs in clinical diagnosis and treatment. In this article the application of oligonucleotideaptamer in the clinical treatment are reviewed from several aspects such as the development of the SELEX technology, the advantages of clinica ligands as target protein modification of ligands, 1 treatment, functions of blocking agents and tar geted drug delivery carrier.